Merck Mumps Vaccines Are a Total Fraud: Company Can Only Provide the Courts with Efficacy Data from 50 Years Ago

A pair of former Big Pharma scientists have accused their former employer, Merck & Co., of falsifying tests of an exclusive mumps vaccine in recently filed court papers, charges they say the pharmaceutical giant has yet to answer.

Lawyers at Constantine Cannon, the firm representing the scientists, have asked U.S. Magistrate Judge Lynne Sitarski of the Eastern District of Pennsylvania to force the company to respond to their request for discovery, which seeks to compel the company to provide efficacy data regarding the vaccine in the form of a percentage.

But, as Reuters reports, rather than answer the question, the letter said, Merck has instead been evasive, using “cut-and-paste” stock answers and claiming that the company cannot run new clinical trials to determine current efficacy. Rather, Merck has only provided data that is five decades old.

“Merck should not be permitted to raise as one of its principal defenses that its vaccine has a high efficacy, which is accurately represented on the product’s label, but then refuse to answer what it claims that efficacy actually is,” the court letter said.

A representative of Merck could not immediately be reached for comment, Reuters noted in its June 4 report.

The news service added:

The two scientists, Stephen Krahling and Joan Wlochowski, filed their whistleblower lawsuit in 2010 claiming Merck, the only company licensed by the Food and Drug Administration to sell a mumps vaccine in the United States, skewed tests of the vaccine by adding animal antibodies to blood samples.

As a result, they said, Merck was able to produce test results showing that the vaccine was 95 percent effective, even though more accurate tests would have shown a lower success rate. The plaintiffs said these false results kept competitors from trying to produce their own mumps vaccines, since they were unable to match the effectiveness Merck claimed.

Ripped off governments”

In 2012, Chatom Primary Care, which is based in Alabama, and two individual physicians – all buyers of the Merck mumps vaccine – filed a proposed antitrust class action based on allegations in the whistleblowers’ suit. The two cases are now being coordinated before Sitarski and U.S. District Judge C. Darnell Jones, said Reuters.

As noted by Natural News editor Mike Adams, the Health Ranger, in this June 2012 report, Merck knowingly falsified its mumps vaccine test data, spiked blood samples with animal antibodies, sold a vaccine “that actually promoted mumps and measles outbreaks, and ripped off governments and consumers who bought the vaccine thinking it was ‘95% effective.'”

As further reported by Courthouse News at the time:

Merck also added animal antibodies to blood samples to achieve more favorable test results, though it knew that the human immune system would never produce such antibodies, and that the antibodies created a laboratory testing scenario that “did not in any way correspond to, correlate with, or represent real life… virus neutralization in vaccinated people,” according to the complaint.

“Falsely represent in its labeling

Merck’s allegedly fraudulent claims were made so that the company could corner the mumps vaccine market, Adams noted, adding that the Merck scientists – who are virologists – state the fraud has been ongoing since the 1990s.

But there is even more complicity, as Adams pointed out:

Rather than taking action on this false claims act, the U.S. government simply ignored it, thereby protecting Merck’s market monopoly instead of properly serving justice. This demonstrates the conspiracy of fraud between the U.S. government, FDA regulators and the vaccine industry.

In its court filing,[PDF] Chatom alleged:

Merck fraudulently represented and continues to falsely represent in its labeling and elsewhere that its Mumps Vaccine has an efficacy rate of 95 percent or higher.

In reality, Merck knows and has taken affirmative steps to conceal — by using improper testing techniques and falsifying test data — that its Mumps Vaccine is, and has been since at least 1999, far less than 95 percent effective. …

Merck designed a testing methodology that evaluated its vaccine against a less virulent strain of the mumps virus. After the results failed to yield Merck’s desired efficacy, Merck abandoned the methodology and concealed the study’s findings.

“Designed to fail

In a separate Natural News report, Rosemary Mathis, Vice President of Victim Support, SANE VAX, INC., pointed out that governments all over the world were defrauded by Merck after purchasing the vaccine. What’s more, the dishonesty has actually led to more calls for more vaccines.

“According to the two whistleblowers, not only have all the multivalent MMR vaccines been sold under false pretenses, but, as a result of this LACK OF EFFICACY, there have been numerous mumps outbreaks worldwide prompting calls for regular MMR boosters throughout life,” she wrote.

In 2013, Adams wrote that Merck’s epic failure and cover-up led to a greater number of outbreaks because the vaccines were “designed to fail.”

“Measles and mumps are making a huge comeback in the United States, but doctors and journalists all make the same critical error in understanding why. They blame ‘parents who don’t vaccinate their kids’ as the cause, but the real cause — as revealed by whistleblowing scientists working for top vaccine manufacturers — is that measles and mumps vaccines are designed to fail from the start,” he wrote.

“Scientific fraud, it turns out, is an inherent part of the vaccine industry.”

Sources:

http://www.reuters.com

http://www.naturalnews.com[PDF]

http://www.naturalnews.com

http://www.truthwiki.org/Vaccine_Fanaticism/

http://www.truthwiki.org/Medical_Fascism/


Articles by: J. D. Heyes

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]